• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Frontage Laboratories makes two senior appointments

Frontage Laboratories makes two senior appointments

July 18, 2013
CenterWatch Staff

George Laskaris and Alma Villasin have joined Frontage Laboratories in senior positions. Laskaris has been named senior director, Frontage Biometrics Services, and Villasin, R.N., B.S.N., M.B.A., joins as director, clinical operations.

Laskaris brings more than 20 years of programming, statistical and data management experience within pharmaceutical and CROs. He will spearhead operational management, infrastructure development and growth strategies for Frontage’s clinical programming, statistics and data management groups. Laskaris joins Frontage from PRA, where he managed a team of statistical programmers.

Villasin will be responsible for day-to-day oversight of clinical operations and staff training for all study activities and for oversight of the company’s clinical operations expansion initiative. Most recently, Villasin was clinical operations director for Duke Clinical Research Unit (DCRU), where she oversaw the feasibility and conduct of phase I-III clinical trials. Prior to DCRU, she worked at Thomas Jefferson University as manager of the clinical trials groups. She led a research collaboration on global cardiovascular phase II/III trials and developed an investigator network in key therapeutic areas such as cardiovascular, endocrinology and family medicine.

The addition of these two positions is part of Frontage’s strategy to expand its full-service early phase clinical services, which include capabilities to conduct a broad range of  studies  as well as broadening protocol development, analysis methodology and reporting services supporting later phase trials and programs.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing